A phase 1/2 trial of Injection of humanized nerve growth factor (NGF) antibody in advanced solid tumours, run by Shenyang Sunshine Pharmaceutical Co., LTD., now recruiting.
Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain is a phase 1/2 interventional study registered as NCT07008703 by Shenyang Sunshine Pharmaceutical Co., LTD., with 132 participants planned, started 2024-03-27 and due to reach its primary completion in 2025-12. Interventions recorded: Injection of humanized nerve growth factor (NGF) antibody.
Shares 3SBio, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares 3SBio, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares 3SBio and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.